Ex vivo modeling of precision immuno-oncology responses in lung cancer
Science Advances · 2024-11 · 10 (44)
DOI: 10.1126/sciadv.adq6830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024-11. Verfasst von Bassel Alsaed und 20 weiteren Autor:innen. Beteiligte Einrichtung: Translational Immunology Research Program (TRIMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Lung Neoplasms, Precision Medicine, Immunotherapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Despite immunotherapy’s promise in cancer treatment, patient responses vary substantially because of the individual nature of the immune system and the lack of reliable biomarkers. To address this issue, we developed a precision ex vivo platform that integrates patient-specific tumor and immune cells to study the mechanisms of antitumor immune response, predict immunotherapy outcomes, and identify effective treatments. This platform revealed unique single-cell immune response mechanisms and sensitivities to standard-of-care immunotherapies. Furthermore, we were able to identify a synergistic combination of anti–programmed cell death protein 1 (anti–PD-1) together with a Casitas B lineage lymphoma-b inhibitor that overcame anti–PD-1 resistance in selected patient samples. Activation of the interferon-γ–stimulated cytokines predicted combination efficacy, while immunosuppressive cytokines were associated with poor response. Our findings underscore the platform’s potential in tailoring immunotherapies and advancing drug development, offering avenues for personalized cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Immunology Research Program (TRIMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
- Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
- Department of General Thoracic and Esophageal Surgery, Heart and Lung Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Translational Cancer Medicine Program (CAN-PRO), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Wihuri Research Institute, Biomedicum Helsinki, Haartmaninkatu 8, Helsinki, Finland.
ORCID-Profile: Bassel Alsaed, Johannes Smolander, Hanna Laitinen, Mikko Räsänen, Karita Peltonen, Emmi Jokinen, Jay Klievink, Keerthana Ganesh, Mari Ainola, Eva Sutinen, Elli Narvi, Pipsa Saharinen, Satu Mustjoki, Ilkka Ilonen, Heidi M Haikala
Zitieren
APA
Alsaed, B., Smolander, J., Laitinen, H., Lin, L., Bobik, N., Lahtinen, L., Räsänen, M., Jansouz, S., Peltonen, K., Jokinen, E., Klievink, J., Ganesh, K., Ainola, M., Sutinen, E., Rönty, M., Narvi, E., Thotakura, A., Saharinen, P., Mustjoki, S., …, & Haikala, H. M. (2024). Ex vivo modeling of precision immuno-oncology responses in lung cancer. Science Advances, 10(44). https://doi.org/10.1126/sciadv.adq6830
Vancouver
Alsaed B, Smolander J, Laitinen H, Lin L, Bobik N, Lahtinen L, et al. Ex vivo modeling of precision immuno-oncology responses in lung cancer. Science Advances. 2024;10(44). doi:10.1126/sciadv.adq6830
BibTeX
@article{Alsaed2024,
author = {Alsaed, Bassel and Smolander, Johannes and Laitinen, Hanna and Lin, Linh and Bobik, Nina and Lahtinen, Lilja and Räsänen, Mikko and Jansouz, Shadi and Peltonen, Karita and Jokinen, Emmi and Klievink, Jay and Ganesh, Keerthana and Ainola, Mari and Sutinen, Eva and Rönty, Mikko and Narvi, Elli and Thotakura, Anil and Saharinen, Pipsa and Mustjoki, Satu and Ilonen, Ilkka and Haikala, Heidi M},
title = {Ex vivo modeling of precision immuno-oncology responses in lung cancer},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {44},
doi = {10.1126/sciadv.adq6830}
}
EUVIMED